Drugs / BR1015-3
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT07421401 Comparator | Apr → Jun 2026 overdue | essential hypertension | Boryung Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06744439 Comparator | Jan → Mar 2025 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06744426 Comparator | Jan → Mar 2025 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR1015-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06744426 ↗ |
| Route | Oral | “Fasting, Oral Administration” NCT07421401 ↗ |